Abstract Genome-wide association studies (GWAS) have shown that single-nucleotide polymorphisms (SNPs) in G6PC2 are the most important common determinants of variations in fasting blood glucose (FBG) levels. Molecular studies examining the functional impact of these SNPs on G6PC2 gene transcription and splicing suggest that they affect FBG by directly modulating G6PC2 expression. This conclusion is supported by studies on G6pc2 knockout (KO) mice showing that G6pc2 represents a negative regulator of basal glucose-stimulated insulin secretion that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux and opposing the action of glucokinase. Suppression of G6PC2 activity might, therefore, represent a novel therapy for lowering FBG and the risk of cardiovascular-associated mortality. GWAS and G6pc2 KO mouse studies also suggest that G6PC2 affects other aspects of beta cell function. The evolutionary benefit conferred by G6PC2 remains unclear, but it is unlikely to be related to its ability to modulate FBG.
Introduction
Over the past 5 years, through the power of genome-wide association studies (GWAS), there has been an explosion in our knowledge with respect to the identity of the genes that confer enhanced risk for the development of type 2 diabetes; over 60 loci have been linked to type 2 diabetes risk [1, 2] . GWAS data have also provided insight into the genes controlling fasting blood glucose (FBG) levels [3, 4] and glycated hemoglobin A1C (HbA1c) levels [5] , as well as the genes associated with increased risk for the development of obesity [6] . Elevated FBG, HbAlc, and body mass are all important traits that are correlated with the risk of developing type 2 diabetes [7] [8] [9] [10] and cardiovascular-associated mortality (CAM) [11] [12] [13] , although, as will be discussed later, the precise relationships between FBG and type 2 diabetes [14•] and between FBG and CAM [15] are still under investigation.
At this point, multiple investigators are performing followup studies on the genes implicated by GWAS in an effort to understand how particular genes contribute to disease risk. This is a difficult proposition because, in many instances, the single nucleotide polymorphisms (SNPs) that have been linked to disease risk fall in intergenic regions. As such, identifying the disease-related gene(s) associated with these SNPs is a significant challenge. In some cases, these intergenic SNPs may impact the function of transcriptional control structures, such as enhancers and silencers [16] , such that the genes whose expression are affected may be located a considerable distance from the SNP, although in the literature, the nearest gene is often assumed to be the likely candidate.
In relation to the GWAS data for type 2 diabetes, several of the disease-associated SNPs fall within specific genes [1] . Some of these genes had already been implicated by other genetic approaches to disease risk (PPARG , KCNJ11 , TCF7L2 ) or had already been shown, or were suspected to have, a role in metabolism (HNF1B), obesity (FTO ), or beta cell biology (SLC30A8) through molecular studies. Several excellent recent reviews have highlighted the progress made in understanding the molecular and physiological mechanisms whereby the FTO , SLC30A8, and TCF7L2 genes contribute to disease risk [17] [18] [19] [20] . However, for most of the genes linked by GWAS to type 2 diabetes, the mechanisms by which the encoded proteins modulate disease risk remain unclear [1] .
With respect to the genes linked to variations in FBG, multiple GWAS have shown that the G6PC2 locus harbors the strongest common genetic determinant of FBG levels in terms of significance and effect size with a common SNP, rs560887, explaining~1 % of the total variance in FBG [3, 4, [21] [22] [23] [24] [25] [26] . Common variants in the GCK gene, which encodes glucokinase, have also been linked to variations in FBG, but the influence of these common GCK variants on FBG is less than that of the common variants in G6PC2 [3] . This observation highlights a critical point-namely, that the magnitude of the effect of common gene variants identified through GWAS does not necessarily correlate with the importance of the gene in relation to the parameter under investigation. With respect to G6PC2 and GCK, deletion of the G6pc2 gene in mice has a mild metabolic phenotype [27, 28•] and rare mutations in G6PC2 are not a cause of monogenic forms of diabetes [29] . In contrast, deletion of the Gck gene in mice is lethal [30] , and rare heterozygous inactivating mutations in GCK are a cause of maturity-onset diabetes of the young, which is characterized by mild fasting hyperglycemia, whereas homozygous inactivating glucokinase mutations result in permanent neonatal diabetes mellitus, which is characterized by severe hyperglycemia [31] . In contrast, glucokinase activating mutations result in hyperinsulinemia leading to hypoglycemia [31] . These rare GCK mutations have provided fascinating molecular insights into the function of glucokinase [31] and, along with mouse models of Gck overexpression [32] and tissue-specific deletion [30, 33] , have contributed greatly to the recognition that glucokinase is the pancreatic islet beta cell glucose sensor [34] . Far less is known about the G6PC2 gene, which is the focus of this review.
G6PC2 Encodes a Glucose-6-Phosphatase Catalytic Subunit
Glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate [35] [36] [37] [38] [39] . It exists as a multicomponent system located in the endoplasmic reticulum and is made up of several integral membrane proteins-namely, a catalytic subunit (G6PC), a glucose transporter, and a G6P/inorganic phosphate antiporter [35] [36] [37] [38] [39] . Three G6PC isoforms have been identified, designated G6PC, G6PC2, and G6PC3 [39] . Each isoform is encoded by a separate gene with a distinct pattern of tissue-specific expression [39] . G6PC2 was originally named IGRP, which stands for islet-specific glucose-6-phosphatase catalytic subunit related protein [40, 41] . The G6PC2 gene is expressed exclusively in pancreatic islet beta cells [42] . G6PC2 is a major autoantigen in both mouse [43] [44] [45] and human [46, 47] type 1 diabetes, but interestingly, GWAS data have not linked G6PC2 SNPs to type 1 diabetes risk [48] .
Correlation Between GWAS and Knockout Mouse Data with Respect to the Regulation of FBG by G6PC2 Taneera et al. [49] have suggested that rs560887, which is located in the third intron of G6PC2, acts in trans to modulate the expression of multiple other genes, but more recent molecular studies [50] , which will be described later, have shown that the "A" allele of rs560887, which is associated with reduced FBG, leads directly to a reduction in G6PC2 expression. As such, these molecular data are consistent with thẽ 15 % decrease in FBG observed following a global knockout (KO) of G6pc2 in mice [27, 28•] . This decrease in FBG is observed when G6pc2 KO mice are studied on a mixed [27] or pure C57BL/6J [28•] genetic background. These mouse data strongly support the hypothesis that genetic variation within the G6PC2 gene, rather than surrounding genes, directly contributes to variations in FBG in humans.
The Mechanism of FBG Regulation by G6PC2
A comparison of glucose-6-phosphatase activity in islets isolated from wild-type and G6pc2 KO mice indicates that activity is abolished in the latter [28•] . These data led to the simple hypothesis that G6pc2 acts as a negative regulator of basal glucose-stimulated insulin secretion (GSIS) by hydrolyzing G6P and, thereby, opposing the action of the glucose sensor, glucokinase [51, 52] (Fig. 1) . This glucokinase/G6pc2 futile substrate cycle is predicted to reduce glycolytic flux and, hence, insulin secretion [28•] . Consistent with this model and human GWAS data, a reduction in G6pc2 expression results in a leftward shift in the dose response curve for GSIS, explaining why, under fasting conditions, blood glucose levels are reduced [28•] . Do GWAS and Knockout Mouse Data Resolve the Historical Controversy Over Islet Glucose-6-Phosphatase?
Historically, the role of glucose-6-phosphatase activity in pancreatic islets has been highly controversial. Initially, there was debate over whether such activity even existed in islets, although, over time, the majority of studies found that activity was detectable, but at a lower level than that found in the liver [36, 40, [53] [54] [55] [56] . However, the harder issue to resolve is whether the level of activity is enough to affect GSIS and, therefore, be of physiological significance. This question has been investigated by several groups. Sweet et al. [56] concluded that, while glucose-6-phosphatase activity is present in rat islets, the level of activity is not enough to result in sufficient G6P hydrolysis so as to affect GSIS. However, the relevance of these rat islet data to the human GWAS data is unclear, because, in contrast to all other vertebrate species examined (see http://genome.ucsc.edu/), G6PC2 is a pseudogene in rats [57] .
The observations of Sweet et al. [56] and the absence of G6PC2 in rats raise the question as to what benefit islet glucose-6-phosphatase activity confers to mice and humans that is dispensable to rats. However, three observations suggest that the premise of this question is not well founded. First, rat islets express low levels of the G6PC isoform, whereas microarray data show no expression of G6pc or G6pc3 in mouse islets (unpublished data). G6PC is predominantly expressed in the liver and kidney, where it catalyzes the final step in the gluconeogenic and glycogenolytic pathways [35] [36] [37] [38] [39] , but in various rat models associated with impaired glucose tolerance, G6PC expression is induced [58] [59] [60] . Second, Pedersen et al. [61] have demonstrated that the rat G6PC promoter is activated strongly by glucose, much more so than the mouse or human G6PC promoters. This implies that the estimates of G6P hydrolysis in rat islets will be very dependent on the glucose concentration in the culture medium and, hence, the level of induction of G6PC . Third, G6PC is~20-fold more active than G6PC2 [62] , such that much less G6PC is required in rat islets to catalyze an equivalent rate of G6P hydrolysis as observed in mouse islets. It therefore appears that G6PC may play the same role in rat islets as G6PC2 does in human and mouse islets.
Several groups have also examined G6P hydrolysis in mouse, rather than rat, islets. One early study suggested that even though glucose-6-phosphatase activity is present in mouse islets, G6P hydrolysis does not occur [63] . This counterintuitive conclusion was challenged by later studies, which showed that the measurement of G6P hydrolysis within islets is critically dependent on experimental conditions [64, 65] . The more recent GWAS and G6pc2 KO mouse data described above, especially the demonstration that G6pc2 accounts for the low glucose-6-phosphatase enzyme activity detected in mouse islets [28•] , would seem to resolve the historical controversy over the importance of glucose-6-phosphatase activity in islets. However, two caveats remain.
The first caveat relates to the fact that estimates of glucose cycling in mouse pancreatic islets are very low [66] . However, these estimates of glucose cycling were generated using radioisotopes, and the methodology involved is associated with a number of assumptions [64, 65] . To avoid these assumptions, it will be essential to reassess the level of glucose cycling in pancreatic islets using more recently developed stable isotope methodology [67] . If the rates of glucose cycling calculated using this technology are greater than previously estimated using radioisotopes, this would support the hypothesis that G6PC2 directly influences GSIS through its ability to hydrolyze G6P. Importantly, because the glucose-6-phosphatase activity of G6PC2 is~20-fold lower than that of Fig. 1 G6PC2 regulates glucose-stimulated insulin secretion (GSIS) by opposing the action of glucokinase. The model shows the best-characterized pathway for GSIS, although studies on potassium channel mutations indicate that other pathways clearly contribute [96] . The glucose-6-phosphate (G6P) transporter (G6PT) and inorganic phosphate transporter are shown in the same color to indicate the fact that G6PT is actually a G6P:Pi antiporter [97] . The model proposes that G6PC2 regulates GSIS by opposing the action of glucokinase, but it also suggests that G6PC2 might modulate islet calcium metabolism through its ability to promote the generation of inorganic phosphate in the endoplasmic reticulum lumen, resulting in the retention of calcium [77] . G6PC [28•, 62] , it heightens the concern that G6PC2 may be influencing GSIS through a mechanism independent of its ability to hydrolyze G6P. Indeed, all three G6PC isoforms possesses a phosphatidic acid phosphatase domain [68] , raising the possibility that they may also have lipid substrates.
Human GWAS Data Provide Novel Insights into the Influence of G6PC2 on GSIS
The second caveat concerning the function of G6PC2 in pancreatic islets relates to the unexpected effects of altered G6PC2 expression on insulin secretion during glucose tolerance tests. This issue was initially uncovered through the analysis of GWAS data, rather than the analysis of G6pc2 KO mice. This provides an interesting example of how GWAS data not only can provide insight into genes linked to the initial parameter under investigation, but also can provide insight into other functions of the genes identified. As was mentioned above, a reduction in G6pc2 expression results in a leftward shift in the dose response curve for GSIS, explaining why, under fasting conditions, blood glucose levels are reduced [28•] . But under conditions of elevated blood glucose, this same leftward shift arising from a reduction in G6pc2 expression should result in increased GSIS. Indeed, in perfused pancreas studies comparing pancreata from wild-type and G6pc2 KO mice, GSIS is increased in the KO pancreata at submaximal glucose concentrations [28•] . Likewise, in isolated islet studies comparing islets from wild-type and G6pc2 KO mice, GSIS is increased in the KO islets at submaximal glucose concentrations [28•] . This increased insulin secretion at submaximal glucose concentrations was predicted to result in improved glucose tolerance in G6pc2 KO mice. However, neither intraperitoneal nor oral glucose tolerance tests show major differences in glucose tolerance or insulin secretion between WT and G6pc2 KO mice over a range of glucose concentrations [28•] .
These observations in G6pc2 KO mice are consistent with earlier human GWAS data showing no association between G6PC2 and glucose tolerance [69] [70] [71] [72] . GWAS data also showed that G6PC2 is not associated with variations in insulin sensitivity in humans [69] [70] [71] [72] , an observation that was confirmed in G6pc2 KO mice [28•] .
To further complicate the situation, human GWAS data show that the SNP within the G6PC2 gene that is associated with reduced G6PC2 expression [50] and reduced FBG [3] is actually associated with a reduction in insulin secretion during glucose tolerance tests, rather than the expected increase [69] [70] [71] [72] . So, in humans, reduced G6PC2 expression appears to promote glycolytic flux, leading to reduced FBG, but this enhanced flux not only fails to enhance glucose tolerance during a glucose challenge, but also is actually associated with a decrease in insulin secretion during that glucose challenge.
The data with G6pc2 KO mice appear slightly different to the human GWAS data in that a similar reduction in insulin secretion was not observed in G6pc2 KO mice during glucose tolerance tests [28•] . However, this may simply be due to the relatively low number of animals analyzed [28•] , relative to the vast number of humans analyzed in GWAS studies [69] . Thus, mouse data are inherently noisy in that significant variations in insulin sensitivity and, hence, insulin secretion are observed even within inbred C57BL/6J mice [73] . The key consistent observation is that in both mice and humans, reduced G6PC2 expression does not lead to an improvement in glucose tolerance.
The unexpected association between reduced G6PC2 expression and reduced insulin secretion during glucose tolerance tests in humans has been hypothesized to indicate that either G6PC2 affects the pulsatility of insulin secretion [69] or that it affects hepatic glucose production rather than beta cell function [72] . The latter explanation appears highly unlikely, since human G6PC2 [3, 57] and mouse G6pc2 [39, 40] are expressed only in islets and not in liver. In contrast, a change in the pulsatility of insulin secretion and, hence, the efficacy of insulin signaling would provide an elegant explanation as to how reduced G6PC2 expression could lead to a reduction in insulin secretion that is not associated with a counterbalancing change in glucose tolerance or insulin sensitivity [69] [70] [71] [72] .
Whether the absence of G6pc2 in mice affects the pulsatility of insulin secretion is a key question that remains to be addressed. However, if this is the explanation for the reduced insulin secretion during glucose tolerance tests in humans, the question arises as to whether the ability of G6PC2 to influence the pulsatility of insulin secretion is dependent on its ability to hydrolyze G6P or some other function, perhaps connected with the phosphatidic acid phosphatase domain mentioned above [68] . The generation of a transgenic model in which a mutated form of G6pc2 lacking glucose-6-phosphatase activity is expressed in the G6pc2 KO mice might provide insight into this question. Merrins et al. [74] have elegantly shown that pulsatile insulin secretion is driven by metabolic oscillations and that the magnitude of the pulses can be amplified by raising intracellular calcium levels. This then raises the question as to whether G6PC2 might affect metabolic oscillations, intracellular calcium levels, or both. Merrins et al. [75] have recently shown that metabolic oscillations in islets are initiated at an early stage in glycolysis with the mechanism likely involving the autocatalytic feedback of fructose 1, 6-bisphosphate onto phosphofructokinase 1, with phosphofructokinase 1 being activated by its product resulting in the subsequent depletion of its substrate [76] . On the basis of these data, it would appear more likely that G6PC2 affects pulsatile insulin secretion through an action on intracellular islet calcium levels, rather than metabolic oscillations. Indeed, basal cytoplasmic calcium levels are enhanced in islets isolated from G6pc2 KO mice [28•] . This increase was interpreted as a secondary event resulting from the enhanced rate of glycolytic flux [28•] , but, on the basis of the studies of Merrins et al. [74] , if this difference was instead, at least in part, a primary consequence of G6pc2 deletion, a difference in intracellular calcium between wild-type and G6pc2 KO islets would be predicted to be associated with altered pulsatile insulin secretion. Indeed, G6PC2 might modulate islet calcium metabolism through its ability to promote the generation of inorganic phosphate in the endoplasmic reticulum lumen, resulting in the retention of calcium [77] (Fig. 1) .
Human GWAS Data Uncover an Unexpected Connection Between G6PC2 and Body Weight
In addition to uncovering the complex relationship between G6PC2 and glucose tolerance, human GWAS data show that G6PC2 is also unexpectedly associated with altered body fat and BMI [69] . The "A" allele of rs560887, which is associated with reduced FBG [3] and with reduced G6PC2 expression [50] , is also associated with reduced body fat and BMI [69] . Subsequently, studies on female G6pc2 KO mice demonstrated a reduction in body fat and body weight on both chow fed and high-fat fed diets, consistent with the human GWAS data [28•] . The reason why similar differences are not observed in male mice is unclear, but the key question is how G6PC2, which is selectively expressed in islets [3, 42] , could impact body fat and body weight. There appear to be three possibilities. The first, as suggested by Li et al. [69] , is that changes in body weight are secondary to altered efficacy of insulin signaling arising from altered pulsatile insulin secretion. But a second possibility is that G6PC2 is expressed elsewhere in the body, in a tissue that can influence body weight. The obvious candidate would perhaps be the hypothalamus, given its wellestablished role in body weight regulation and the fact that glucokinase is also expressed there [78] . Goh et al. [79] have reported very low G6pc2 expression in mouse hypothalamus, but only at very high template concentrations and PCR cycles. Furthermore, the gene encoding the catalytically more active G6pc3 isoform was expressed at much higher levels [79] , such that the loss of barely detectable G6pc2 expression would likely have little impact on total hypothalamic glucose-6-phosphatase activity. Of note, an analysis of multiple G6pc2-LacZ transgenes failed to detect hypothalamic expression [27, 80, 81] . Finally, a third possibility for explaining the connection between G6PC2 and body weight relates to the kinetics of GSIS. The same model that predicts a leftward shift in the dose response curve for GSIS following a reduction in G6PC2 expression [28•] would predict a faster rise in plasma insulin levels as glucose levels rise following a meal. Since insulin is a satiety factor [82] , the more rapid rise in plasma insulin might lead to an earlier cessation of feeding and, hence, a reduction in food intake and body mass. Further studies in G6pc2 KO mice should be able to address this hypothesis.
Evolution and the Function of G6PC2
An intriguing aspect of the human GWAS data discussed above is the conclusion that the absence of G6PC2 would be beneficial to several aspects of human health. In relation to FBG, it would be lowered by the absence of G6PC2, which would be predicted to reduce the risk of cardiovascularassociated mortality and type 2 diabetes (but see below). Similarly, in relation to body fat and BMI, both would be lowered by the absence of G6PC2, with the expected health benefits. Finally, the human GWAS data imply that, if G6PC2 is affecting the pulsatility of insulin secretion and, hence, the efficacy of insulin signaling, this pulsatility is actually enhanced by the absence of G6PC2, explaining the reduced insulin secretion during glucose tolerance tests [69] .
Since the presence of G6PC2 has been retained through mammalian evolution, with the exception of rats, this implies that there must be beneficial effects conferred by G6PC2 that are not apparent from the human GWAS data. The health benefits conferred by reduced FBG and BMI are unlikely to be relevant to reproductive potential, since the diseases associated with elevated FBG and BMI typically occur later in life, long after individuals have passed on their genetic material to their offspring. Furthermore, such diseases are prevalent only in the modern world and would not even have been a factor during the course of evolution.
The biological benefit(s) conferred by the presence of G6PC2 are currently unknown, but one possibility is that G6PC2 expression or G6PC2 enzyme activity is activated under specific physiological conditions. This would have the effect of shifting the dose response curve for GSIS to the right, resulting in reduced insulin secretion (Fig. 2) . A number of studies have suggested that the activity of hepatic G6PC is altered by insulin signaling [83] , although, because the mechanisms involved are unknown, it is unclear whether the same signaling pathway might regulate G6PC2 enzyme activity. Similarly, while multiple transcription factors that contribute to the islet beta-cell-specific expression of G6PC2 have been identified [39] , there is currently no evidence that G6PC2 expression is modulated in vivo under different physiological conditions. Nonetheless, there is circumstantial data to support the potential impact of altered G6PC2 expression. First, in various rat models associated with impaired glucose tolerance, G6PC expression is induced such that G6P hydrolysis would be elevated and GSIS blunted [58] [59] [60] . This induction may play a protective role against excessive stimulation of the beta cells, which is a concern given their susceptibility to ER [84] and oxidative stress [85] . Second, experiments in which G6PC was overexpressed in pancreatic islet beta-cell-derived cell lines using adenovirus [86] or stable transfection [87] have directly demonstrated that altered expression of this single gene is sufficient to inhibit insulin secretion.
The Relationship Between G6PC2, FBG, and Type 2 Diabetes Risk
Since G6PC2 is associated with variations in FBG and HbA1c [3, 4, [21] [22] [23] [24] [25] [26] and because the accepted dogma is that elevated FBG and HbA1c are associated with an increased risk for the development of type 2 diabetes [7] [8] [9] , one would logically have expected that G6PC2 would also be associated with increased risk for the development of type 2 diabetes. Indeed, studies on Chinese individuals have shown such an association [24, 25] , although the sample sizes used in these studies were relatively small. Other studies, with large sample sizes, have shown that in European populations, G6PC2 is linked to variations in FBG, but not risk for the development of type 2 diabetes [22, 23] . In contrast, a recent meta-analysis contradicted these conclusions and described an association between G6PC2 and type 2 diabetes risk in Caucasians but not Asians [88] . Adding to the confusion, this potential discordance in the connection between G6PC2, FBG, and type 2 diabetes risk does not apply to other genes that have been linked to variations in FBG. For example, variations in GCK are linked to both FBG and type 2 diabetes risk [23] .
A study by Abdul-Ghani et al. [14• ] provides a potentially elegant resolution to this paradox. They have reported that the 1-h glucose level in a glucose tolerance test is a better predictor of type 2 diabetes risk than FBG, such that, after correcting for this variable, the association between FBG levels and type 2 diabetes risk is lost. The authors suggest that the apparent correlation between elevated FBG and type 2 diabetes risk is not due to the increase in FBG per se but is due, instead, to the correlation between FBG and 1-h glycemia [14•] . On the basis of the observations of Abdul-Ghani et al. [14•] , one would predict that variations in GCK would affect both 1-h glucose levels in a glucose tolerance test, in addition to FBG, whereas variations in G6PC2 would affect only the latter (Fig. 3) . Indeed, the rs1799884 GCK variant is associated with higher 1-h glucose levels [89] . In some populations [89] , although not in others [69] , this variant is also associated with higher 2-h glucose levels. In contrast, the rs560887 G6PC2 variant is not associated with altered glucose tolerance [69] [70] [71] [72] . The observations of Abdul-Ghani et al. [14• ] also lead to the conclusion that the observed decrease in G6PC2 expression in islets from donors with type 2 diabetes [49] is likely to be a secondary event-specifically, a response to the diabetic environment-rather than a causative event that contributes to the development of type 2 diabetes. Thus, on the basis of G6pc2 KO mouse data [27, 28•] , a decrease in G6PC2 expression would lead to enhanced insulin secretion, which would make sense in terms of a compensatory attempt by unhealthy islets to maintain insulin secretion.
As is described below, the rs560887 G6PC2 variant linked by GWAS to FBG, but not to type 2 diabetes risk, is predicted to have only a small effect on G6PC2 expression [50] . However, even though small changes in G6PC2 expression are not associated by GWAS with the risk for type 2 diabetes, this would not exclude the possibility that rare variants that markedly elevate G6PC2 expression or increase activity may be associated with altered risk for type 2 diabetes. Fig. 2 Elevated G6PC2 expression or enzyme activity would alter the sensitivity of glucose-stimulated insulin secretion (GSIS). The evolutionary function of G6PC2 is unknown but is unlikely to be related to the control of FBG. The model speculates that under specific physiological conditions, G6PC2 expression or enzyme activity is elevated, changing the sensitivity of GSIS. This model is consistent with the observations that a reduction in G6PC2 expression [28•] or Gck overexpression [98, 99] augments glycolytic flux and causes a leftward shift in the dose response curve for GSIS Fig. 3 Variations in GCK but not G6PC2 affect type 2 diabetes risk. Data from genome-wide association studies show that single-nucleotide polymorphisms (SNPs) in both G6PC2 and GCK are associated variations in fasting blood glucose (FBG) but only SNPs in GCK are associated with type 2 diabetes risk. The model proposes that this observation is explained by the fact that SNPs in GCK are associated variations in 1-h glucose levels during a glucose tolerance test, whereas SNPs in G6PC2 are not. This concept is based on the studies of Abdul-Ghani et al. [14•] , who showed that the 1-h glucose level in a glucose tolerance test is a better predictor of type 2 diabetes risk than FBG, such that, after correcting for this variable, the association between FBG levels and type 2 diabetes risk is lost
Functional Analysis of SNPs That Modulate G6PC2 Splicing and Gene Transcription
Several studies have examined the molecular effects of SNPs on G6PC2 splicing and gene transcription. Two SNPs in the G6PC2 promoter, rs13431652 and rs2232316, were shown to affect G6PC2 fusion gene expression by modulating NF-Y and Foxa2 binding, respectively [50, 90] . In addition, two SNPs in the third G6PC2 intron, rs560887 and rs2232321, were shown to affect G6PC2 RNA splicing [50] -likely, by modulating the strength of a branch point sequence, a key element in RNA splicing [91, 92] . The in vitro and in situ molecular data suggest that all four SNPs are potentially causative, since the allele that results in elevated G6PC2 expression is associated with elevated FBG [50, 90] . In contrast, for another G6PC2 promoter SNP, rs573225, that also affects G6PC2 fusion gene expression by modulating Foxa2 binding, the allele that results in elevated G6PC2 expression is associated with reduced FBG [50, 90] , suggesting that rs573225 is a functional SNP that opposes the action of causative SNPs on G6PC2 expression [50, 90] , a conclusion that contrasts with an earlier study [93] .
Challenges in the Identification of Causative G6PC2 SNPs
There are several key limitations in the analysis of G6PC2 causative SNPs. First, because these SNPs are in high linkage disequilibrium, it is difficult to definitely determine whether one or all of these SNPs are truly causative [50, 90] . Second, because the G6PC2 gene is expressed only in pancreatic islet beta cells and because the effects of these SNPs are subtle, the lack of sufficient human samples has limited the ability to correlate genotypes with endogenous G6PC2 expression. Finally, multiple caveats are associated with analyzing G6PC2 promoter SNPs using fusion genes in islet-derived cell lines [50, 90] . Furthermore, most of these cell lines are derived from rodent islets, and recent studies suggest the existence of significant differences between rodent and human islets [94] .
Conclusions and Future Directions
The GWAS and molecular studies described above strongly suggest that G6PC2 modulates FBG by hydrolyzing G6P, thereby opposing the action of the beta cell glucose sensor, glucokinase. However, these studies suggest that G6PC2 has other unexplained effects on islet beta cell function that merit further investigation. The evolutionary benefit conferred by G6PC2 remains unclear, but it is unlikely to be related to its ability to modulate FBG. The identification of rare SNPs that markedly affect G6PC2 enzyme activity and the analysis of the biological impact of these SNPs might provide further insight into G6PC2 function, as have similar studies with glucokinase. Finally, because G6PC2 opposes the action of glucokinase, suppression of G6PC2 activity might represent a novel therapy to lower FBG and HbA1c levels and, hence, the risk of CAM. It is noteworthy that the alternate strategy, the use of GCK activators, has shown promise with several compounds currently in clinical trials [52, 95] .
